Sodium-glucose cotransporter-2 inhibitors and ketoacidosis in heart failure: analysis of US Adverse Event Reporting System (FAERS).
作者信息
Yeung Samantha L, Wang Mengxi, Lou Mimi, Ng Tien M H
机构信息
Titus Family Department of Clinical Pharmacy, University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, 1985 Zonal Ave, Los Angeles, CA 90089-9121, USA.
出版信息
Eur Heart J Open. 2025 May 14;5(3):oeaf056. doi: 10.1093/ehjopen/oeaf056. eCollection 2025 May.
Abstract
摘要
相似文献
1
Sodium-glucose cotransporter-2 inhibitors and ketoacidosis in heart failure: analysis of US Adverse Event Reporting System (FAERS).钠-葡萄糖协同转运蛋白2抑制剂与心力衰竭中的酮症酸中毒：美国不良事件报告系统（FAERS）分析
Eur Heart J Open. 2025 May 14;5(3):oeaf056. doi: 10.1093/ehjopen/oeaf056. eCollection 2025 May.
2
Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.与 SGLT2 抑制剂治疗相关的酮症酸中毒：FAERS 数据分析。
Diabetes Metab Res Rev. 2017 Nov;33(8). doi: 10.1002/dmrr.2924. Epub 2017 Sep 29.
3
Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System.利用美国食品药品监督管理局不良事件报告系统，研究钠-葡萄糖协同转运蛋白2抑制剂与其他降糖药物对室性心律失常或心源性猝死的影响。
Cardiovasc Drugs Ther. 2024 Dec 4. doi: 10.1007/s10557-024-07653-2.
4
Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.钠-葡萄糖共转运蛋白 2 抑制剂与美国食品药品监督管理局不良事件报告系统中的肾癌。
Eur J Clin Pharmacol. 2024 Dec;80(12):1959-1966. doi: 10.1007/s00228-024-03759-6. Epub 2024 Sep 17.
5
SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.钠-葡萄糖协同转运蛋白 2 抑制剂与 FAERS 中的血糖正常糖尿病酮症酸中毒/糖尿病酮症酸中毒：一项药物警戒评估。
Acta Diabetol. 2023 Mar;60(3):401-411. doi: 10.1007/s00592-022-02015-6. Epub 2022 Dec 28.
6
Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.与钠-葡萄糖共转运蛋白 2 抑制剂相关的 Fournier 坏疽：来自美国 FDA 不良事件报告系统的药物警戒研究。
J Diabetes Res. 2020 Jul 8;2020:3695101. doi: 10.1155/2020/3695101. eCollection 2020.
7
A Survey of the FDA's Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use.关于泌尿生殖道感染与钠-葡萄糖协同转运蛋白2抑制剂使用情况的美国食品药品监督管理局不良事件报告系统数据库调查。
Diabetes Ther. 2019 Jun;10(3):1043-1050. doi: 10.1007/s13300-019-0611-9. Epub 2019 Apr 5.
8
Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.钠-葡萄糖协同转运蛋白2抑制剂治疗生殖器真菌感染和尿路感染的药物警戒：食品药品监督管理局不良事件报告系统数据库综述
J Pharm Technol. 2018 Aug;34(4):144-148. doi: 10.1177/8755122518760984. Epub 2018 Feb 23.
9
Correlations Between SGLT-2 Inhibitors and Acute Renal Failure by Signal Detection Using FAERS: Stratified Analysis for Reporting Country and Concomitant Drugs.应用 FAERS 信号检测法评估 SGLT-2 抑制剂与急性肾衰竭的相关性：按报告国家和伴随药物分层分析。
Clin Drug Investig. 2021 Mar;41(3):235-243. doi: 10.1007/s40261-021-01006-9. Epub 2021 Feb 10.
10
Differences in the Adverse Event Profiles of Sodium-Glucose Cotransporter 2 Inhibitors used in Patients with Diabetes Mellitus and Heart Failure: An Analysis Using the Japanese Adverse Drug Event Report Database.糖尿病合并心力衰竭患者使用的钠-葡萄糖共转运蛋白 2 抑制剂的不良事件谱差异：利用日本不良药物事件报告数据库进行的分析。
Clin Drug Investig. 2024 Oct;44(10):761-771. doi: 10.1007/s40261-024-01394-8. Epub 2024 Oct 14.
本文引用的文献
1
Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression.钠-葡萄糖协同转运蛋白2抑制剂相关的糖尿病酮症酸中毒风险：一项网状Meta分析和Meta回归分析
J Clin Med. 2024 Mar 18;13(6):1748. doi: 10.3390/jcm13061748.
2
Therapy of Type 2 diabetes: more gliflozines and less metformin?2型糖尿病的治疗：更多的格列净类药物还是更少的二甲双胍？
Eur Heart J Suppl. 2023 Apr 21;25(Suppl B):B171-B176. doi: 10.1093/eurheartjsupp/suad098. eCollection 2023 Apr.
3
Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial.急性心力衰竭患者循环酮体水平的纵向变化：EMPA-Response-AHF试验的事后分析
J Card Fail. 2023 Jan;29(1):33-41. doi: 10.1016/j.cardfail.2022.09.009. Epub 2022 Oct 14.
4
Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 Inhibitors: a Nationwide Cohort Study in the USA.确定与 SGLT2 抑制剂相关的糖尿病酮症酸中毒的风险因素：美国全国队列研究。
J Gen Intern Med. 2021 Sep;36(9):2601-2607. doi: 10.1007/s11606-020-06561-z. Epub 2021 Feb 9.
5
Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.血糖正常的酮症酸中毒作为 SGLT2 抑制剂治疗的一种并发症。
Clin J Am Soc Nephrol. 2021 Aug;16(8):1284-1291. doi: 10.2215/CJN.17621120. Epub 2021 Feb 9.
6
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.索格列净治疗伴有近期恶化心力衰竭的糖尿病患者。
N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
7
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.钠-葡萄糖协同转运蛋白2抑制剂与糖尿病酮症酸中毒：来自美国食品药品监督管理局不良事件报告系统的数据
Diabetologia. 2017 Aug;60(8):1385-1389. doi: 10.1007/s00125-017-4301-8. Epub 2017 May 12.
8
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.卡格列净治疗2型糖尿病临床项目中的糖尿病酮症酸中毒及相关事件
Diabetes Care. 2015 Sep;38(9):1680-6. doi: 10.2337/dc15-1251. Epub 2015 Jul 22.
Zotero 插件